First Tracks Biotherapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRAX research report →
Range $46 – $100
Price Chart
About the company
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
- CEO
- Daniel R. Faga
- IPO
- 2026
- Employees
- 104
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on TRAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.10B
- P/E
- -12.94
- PEG
- -0.13
- P/S
- 0.00
- P/B
- 6.48
- EV/EBITDA
- -10.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.25%
- ROIC
- -50.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-139,614,000+8.4%
- Op Income
- $-179,006,000
- Net Income
- $-166,087,000-1.5%
- EPS
- $0.00+0.0%
- OCF Growth
- -13.6%
- FCF Growth
- -13.4%
- 52W High
- $49.91
- 52W Low
- $14.72
- 50D MA
- $40.73
- 200D MA
- $29.39
- Beta
- 3.37
- RSI (14)
- 36
- Avg Volume
- 738.52K
No earnings-call transcripts are available for TRAX yet.
- Free Float
- 86.6%
- Shares Outstanding
- 34.89M
- Float Shares
- 30.22M
of shares held by institutions
153 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ecor1 Capital, LLC | 3.17M | ▲ 3.17M |
| Tcg Crossover Management, LLC | 2.90M | ▲ 2.90M |
| Fmr LLC | 2.05M | ▲ 2.05M |
| Affinity Asset Advisors, LLC | 2.03M | ▲ 2.03M |
| Blackrock, Inc. | 1.96M | ▲ 1.96M |
| Trails Edge Capital Partners, LP | 1.51M | ▲ 1.51M |
| State Street Corp | 1.51M | ▲ 1.51M |
| Vanguard Capital Management LLC | 1.45M | ▲ 1.45M |
| Jupiter Topco LLC | 1.09M | ▲ 1.09M |
| Vestal Point Capital, LP | 1.01M | ▲ 1.01M |
| Woodline Partners LP | 917.18K | ▲ 917.18K |
| Sanofi | 821.92K | ▲ 821.92K |
Held by 200 ETFs
Biggest fund positions in TRAX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | ANAPTYSBIO, INC | other | 100 |
| Apr 1, 26 | ANAPTYSBIO, INC | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRAX coverage
Recent articles, reports, and earnings notes.
No research on TRAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRAX report →Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
defenseworld.net · Sep 7
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
globenewswire.com · Aug 26
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
benzinga.com · Aug 13
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 12
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net · Jul 17
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com · May 21
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com · May 21
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.